Pharmafile Logo
Pharmafocus logo
Advanced Search

Yondelis

Showing 6 posts of 6 posts found.

NICE

NICE recommends ovarian cancer drug Caelyx

September 27, 2013
Sales and Marketing NICE, Yondelis, ovarian cancer

News
Caribbean tunicate Ecteinascidia turbinata

NICE gives final no to PharmaMar’s Yondelis

April 27, 2011
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

A lack of evidence and an unconvincing patient access scheme has seen PharmaMar fail to win NICE backing for its …

News
Yondelis - tunicate Ecteinascidia turbin

NICE rejects PharmaMar’s ovarian cancer drug Yondelis

March 14, 2011
Sales and Marketing Cancer, NICE, PharmaMar, Trabectedin, Yondelis, ovarian cancer

NICE has rejected PharmaMar’s ovarian cancer drug in final draft guidance due to a lack of ‘robust’ data. Yondelis (trabectedin) …

News
Ecteinascidia turbinata

NICE rejects Yondelis in ovarian cancer

June 21, 2010
Sales and Marketing NICE, PharmaMar, Yondelis, ovarian cancer

New cancer treatment Yondelis has been rejected by NICE in a preliminary ruling on its use in relapsed ovarian cancer. …

News

Zeltia continue strong growth

February 26, 2010
Sales and Marketing 2009 financials, PharmaMar, Yondelis, Zeltia

Consolidated revenues at Spanish biopharmaceutical company Zeltia increased by 17% to 123.4 million euros enabling it to halve operating losses. …

News

NICE approves Yondelis

February 24, 2010
Sales and Marketing NICE, PharmaMar, Yondelis

Cancer drug Yondelis has been approved by NICE for use on the NHS, but only after the manufacturer offered to …

News
The Gateway to Local Adoption Series

Latest content

STADA and Bio-Thera’s Gotenfia receives positive CHMP opinion for autoimmune diseases

December 18, 2025

Norgine enters exclusive licensing agreement with Vir Biotechnology

December 18, 2025

Incyclix appoints Kimberly Blackwell to Board of Directors

December 17, 2025

Hansa Biopharma appoints Max Sakajja as Vice President, General Manager Europe and International

December 17, 2025

GSK’s Exdensur receives MHRA approval for asthma and rhinosinusitis

December 16, 2025